Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.750
-0.220 (-5.54%)
At close: Feb 21, 2025, 4:00 PM
3.760
+0.010 (0.27%)
After-hours: Feb 21, 2025, 5:59 PM EST
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 5.15, with a low estimate of 3.00 and a high estimate of 6.60. The average target predicts an increase of 37.33% from the current stock price of 3.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Reiterates $4 → $6 | Strong Buy | Reiterates | $4 → $6 | +60.00% | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $6.6 | Strong Buy | Maintains | $6 → $6.6 | +76.00% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $3 | Buy → Hold | Downgrades | $3 | -20.00% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +60.00% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +60.00% | May 31, 2024 |
Financial Forecast
Revenue This Year
205.08M
from 163.91M
Increased by 25.11%
Revenue Next Year
244.64M
from 205.08M
Increased by 19.29%
EPS This Year
-0.41
from -0.45
EPS Next Year
-0.22
from -0.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 213.7M | 273.0M | 341.7M | |||
| Avg | 205.1M | 244.6M | 292.0M | |||
| Low | 194.9M | 213.7M | 241.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 30.4% | 33.1% | 39.7% | |||
| Avg | 25.1% | 19.3% | 19.4% | |||
| Low | 18.9% | 4.2% | -1.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.38 | -0.05 | 0.21 | |||
| Avg | -0.41 | -0.22 | 0.06 | |||
| Low | -0.44 | -0.29 | -0.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.